These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36671475)

  • 1. Screening of Tumor Antigens and Construction of Immune Subtypes for mRNA Vaccine Development in Head and Neck Squamous Cell Carcinoma.
    Li HX; Liu TR; Tu ZX; Xie CB; Wen WP; Sun W
    Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of tumor antigens and immune subtypes in head and neck squamous cell carcinoma for mRNA vaccine development.
    Chen Y; Jiang N; Chen M; Sui B; Liu X
    Front Cell Dev Biol; 2022; 10():1064754. PubMed ID: 36467412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development.
    Huang X; Zhang G; Tang T; Liang T
    Mol Cancer; 2021 Mar; 20(1):44. PubMed ID: 33648511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development.
    Huang X; Tang T; Zhang G; Liang T
    Mol Cancer; 2021 Mar; 20(1):50. PubMed ID: 33685460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development.
    Ma S; Ba Y; Ji H; Wang F; Du J; Hu S
    Front Immunol; 2021; 12():738435. PubMed ID: 34603319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.
    Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D
    Front Immunol; 2022; 13():773264. PubMed ID: 35185876
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Chen L; Lin J; Lan B; Xiong J; Wen Y; Chen Y; Chen CB
    Comput Math Methods Med; 2022; 2022():5851755. PubMed ID: 36510584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of tumor antigens and immune subtypes of acute myeloid leukemia for mRNA vaccine development.
    Wang F
    Clin Transl Oncol; 2023 Jul; 25(7):2204-2223. PubMed ID: 36781600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine.
    Zhong H; Liu S; Cao F; Zhao Y; Zhou J; Tang F; Peng Z; Li Y; Xu S; Wang C; Yang G; Li ZQ
    Front Immunol; 2021; 12():709986. PubMed ID: 34512630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Analyses of Immune Subtypes of Stomach Adenocarcinoma for mRNA Vaccination.
    You W; Ouyang J; Cai Z; Chen Y; Wu X
    Front Immunol; 2022; 13():827506. PubMed ID: 35874675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
    Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
    Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
    [No Abstract]   [Full Text] [Related]  

  • 12. Identification of Tumor Antigens and Immune Subtypes of Esophageal Squamous Cell Carcinoma for mRNA Vaccine Development.
    Lu T; Xu R; Wang CH; Zhao JY; Peng B; Wang J; Zhang LY
    Front Genet; 2022; 13():853113. PubMed ID: 35734437
    [No Abstract]   [Full Text] [Related]  

  • 13. Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma.
    Zhou Q; Yan X; Zhu H; Xin Z; Zhao J; Shen W; Yin W; Guo Y; Xu H; Zhao M; Liu W; Jiang X; Ren C
    Theranostics; 2021; 11(20):9775-9790. PubMed ID: 34815785
    [No Abstract]   [Full Text] [Related]  

  • 14. Dissection of tumor antigens and immune landscape in clear cell renal cell carcinoma: Preconditions for development and precision medicine of mRNA vaccine.
    Hu J; Mo Z
    Math Biosci Eng; 2023 Jan; 20(2):2157-2182. PubMed ID: 36899527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of lung adenocarcinoma tumor antigens and ferroptosis subtypes for developing mRNA vaccines.
    Chen Y; Zhang C; Li Y; Tan X; Li W; Tan S; Liu G
    Sci Rep; 2024 Feb; 14(1):3219. PubMed ID: 38331967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HtrA3: a promising prognostic biomarker and therapeutic target for head and neck squamous cell carcinoma.
    Chen Y; Yang J; Jin H; Wen W; Xu Y; Zhang X; Wang Y
    PeerJ; 2023; 11():e16237. PubMed ID: 37842043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Potential Biomarkers and Survival Analysis for Head and Neck Squamous Cell Carcinoma Using Bioinformatics Strategy: A Study Based on TCGA and GEO Datasets.
    Shen Y; Liu J; Zhang L; Dong S; Zhang J; Liu Y; Zhou H; Dong W
    Biomed Res Int; 2019; 2019():7376034. PubMed ID: 31485443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
    Sun K; Chen RX; Li JZ; Luo ZX
    Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of a fourteen- innate immunity-related gene pairs signature for predicting prognosis head and neck squamous cell carcinoma.
    Zhang F; Liu Y; Yang Y; Yang K
    BMC Cancer; 2020 Oct; 20(1):1015. PubMed ID: 33081731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AVPR2 is a potential prognostic biomarker and correlated with immune infiltration in head and┬áneck squamous cell carcinoma.
    Mao L; Pan Z; Chen W; Hu W; Chen X; Dai H
    BMC Med Genomics; 2023 Mar; 16(1):67. PubMed ID: 36998036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.